Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Menorrhagia Stories

2008-09-10 15:00:37

Reportlinker.com announces that a new market research report related to the Surgical material industry is available in its catalogue. World Uro-Gynecological Surgical Devices Market http://www.reportlinker.com/p092549/World-Uro-Gynecological-Surgical-Devices--Market.html This report analyzes the worldwide markets for Uro-Gynecological Surgical Devices in US$ Million. The major product segments analyzed are Urological Surgical Devices (Sling & Suspension Devices, & Other...

2008-09-09 09:00:09

ROCKLAND, Mass., Sept. 9 /PRNewswire/ -- Supermodel Beverly Johnson is on a mission to get women to Ask 4 questions and Tell 4 or more others about a health condition faced by up to 75 percent of all women in the U.S.(1): uterine fibroids. Although uterine fibroids are common, many women remain uninformed about this condition, and a majority wait up to a year before finding treatment, often despite pain, heavy bleeding and weight gain. Beverly did, and now she is sharing her story to ensure...

2008-09-09 09:00:08

WAYNE, N.J., Sept. 9 /PRNewswire/ -- Nina Garcia, judge of the Emmy-nominated series Project Runway, and the Step Up Women's Network are proud to announce the winner of the "YAZ(R): Step Up and Go Beyond" contest -- aspiring handbag designer Elayne Mayes of Green Village, New Jersey. Elayne's winning design will allow her to jumpstart her fashion design career with a $10,000 prize. Designed to empower women to go beyond what they thought was possible and achieve their career goals, the...

2008-09-08 09:00:52

Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that its third party data management consultants have confirmed that the results from the Company's recently completed Phase II clinical trial evaluating vaginal lidocaine for the prevention and treatment of dysmenorrhea (a condition typified by painful menstruation) will be available on or before September 29, 2008. The Company had previously expected top line data to be available at the end of August. Robert S. Mills,...

2008-09-04 03:00:07

PMS is that dreaded term that many women - and men - dread every month. The emotional rollercoaster is thought to affect about eight out of 10 women - however, many younger women don't realise they have it and are being treated for depression and anxiety instead. There are lifestyle and diet changes you can try that could make all the difference. We reveal how you too can help manage pre-menstrual monsters. ACCORDING to the latest research, 84 per cent of women wrestle with the...

2008-09-02 21:00:05

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. today announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or...

2008-08-18 06:00:14

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that based on the robust efficacy demonstrated by Proellex(R) in the interim assessment of the Company's Phase II endometriosis study, there are sufficient patients currently enrolled to provide for adequate power calculations for the Phase III endometriosis trials. Because of the profound effect noted in this interim analysis, the Company has decided to curtail further patient recruitment for the study. Based on this decision, greater...

2008-08-05 09:01:31

NEWPORT, Ky., Aug. 5 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today positive top line results in two pivotal Phase 3 clinical trials of its proprietary investigational product, a modified-release (MR) formulation of tranexamic acid for the treatment of women with menorrhagia, or heavy menstrual bleeding, and its accompanying symptoms. "We are extremely pleased with the initial data from these pivotal trials and we look forward to continuing to work with the U.S. Food and...

2008-07-21 06:00:17

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the results of the initial Phase I/II clinical trial of Proellex(R) which was conducted in Europe are to be published in US Obstetrics and Gynecology Review in early August. In this study, women with fibroids were treated with Lucrin(R) (also known as Lupron(R)), one of three doses of Proellex, or placebo. Decreases in fibroid size were detected by ultrasound and there was a notable reduction in vaginal bleeding. The drug appeared...

2008-07-17 09:00:19

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is...